Search the Newsreel

Sei Investments Co. Acquires 38,263 Shares of DexCom, Inc. $DXCM

Sei Investments Co. increased its stake in DexCom, Inc. by 42.4% in the first quarter, adding 38,263 shares to reach a total of 128,467 shares valued at $8.1 million. This increase comes as DexCom reported strong quarterly earnings, beating consensus estimates with $0.70 EPS …

DexCom (DXCM) family trust plans 2,000-share stock sale after recent disposals

The Foletta Family Trust, associated with DexCom (DXCM), plans to sell 2,000 shares of common stock, valued at $170,640.00, through UBS Financial Services on NASDAQ, as indicated in a Form 144 filing. These shares originate from vested RSUs granted in 2019. This planned sale …

Form 144 DEXCOM INC For: 3 August By Investing.com

This article announces the filing of Form 144 for DEXCOM INC on August 3rd. It is a brief news update from Investing.com, typical of financial reporting on regulatory filings. The article itself contains minimal content beyond the title and filing date, serving primarily as …

DexCom Inc (DXCM) lifts 16.6% as weekly chart turns higher

The medical-device stock’s medium-term advance is being supported by active trend readings and heavier turnover.

DexCom (DXCM) Recently Broke Out Above the 20-Day Moving Average

DexCom (DXCM) has recently broken above its 20-day moving average, signaling a short-term bullish trend. This technical indicator, combined with a 17.1% increase in stock price over the last four weeks and a Zacks Rank #2 (Buy), suggests potential for further gains. Investors are …

DexCom, Inc. (DXCM) Hit a 52 Week High, Can the Run Continue?

DexCom (DXCM) recently hit a new 52-week high of $84.7, driven by consistent positive earnings surprises and strong growth projections for both current and next fiscal years. The stock currently holds a Zacks Rank #2 (Buy) and favorable Style Scores for Growth and Momentum, …

DexCom: Still A Cautious Buy Following Earnings (NASDAQ:DXCM)

DexCom (DXCM) Is Up 16.6% After Raising 2026 Revenue Guidance And Margin Outlook - Has The Bull Case Changed?

DexCom (DXCM) recently reported strong second-quarter results, including US$1,308.4 million in revenue and US$249.1 million in net income. The company has also raised its full-year 2026 revenue guidance to US$5.18 billion–US$5.25 billion and increased its operating margin expectations to 23.5% to 24%. This positive …

DexCom (DXCM) sube un 16,6 % tras revisar al alza sus previsiones de ingresos y márgenes para 2026: ¿ha cambiado el panorama alcista?

DexCom (DXCM) Stock Sees Fair Value Lift After Analyst Target Increases

DexCom's fair value estimate has increased from US$85.24 to US$91.64, driven by positive analyst commentary following strong Q2 results and a raised full-year outlook. While many analysts are raising price targets due to robust growth prospects in continuous glucose monitoring and strong margins, some …

July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat

The healthcare sector outperformed the S&P 500 in July, gaining 2.45% due to strong company-specific earnings and catalysts. Regeneron, DexCom, and Baxter International were top performers, driven by solid earnings and favorable guidance. In contrast, Moderna and managed-care stocks retreated due to negative pipeline …

DexCom (DXCM) Stock Surges On Margin Strength And Raised Outlook

A Look at DexCom Inc (DXCM) After 11.9% Gain -- GF Value $104.93 vs Price $83.45

DexCom Inc (DXCM) shares recently gained 11.9%, trading at $83.45, which is significantly below its GF Value™ of $104.93, indicating it is "Modestly Undervalued" with a 20.5% upside potential. Despite a strong GF Score™ of 92/100, reflecting robust financial health and growth, recent insider …

DEXCOM INC : RAYMOND JAMES RAISES TARGET PRICE TO $94 FROM $91

Raymond James has increased its target price for Dexcom Inc (DXCM.O) to $94 from the previous $91. This update reflects a positive analyst outlook for the medical device company.

DexCom Inc (DXCM) GF Score of 92/100 Signals Strong Outperformance Potential

DexCom Inc (DXCM) has achieved a GF Score of 92 out of 100, indicating strong outperformance potential due to its robust financial standing, profitability, and growth metrics. The company, a leader in continuous glucose monitoring (CGM) systems, demonstrates exceptional strength in growth (10/10), and …

RBC Capital raises DexCom stock price target to $90 on Q2 beat

RBC Capital has increased its price target for DexCom Inc. shares to $90 from $85, maintaining an Outperform rating after the company's strong second-quarter performance and raised guidance. DexCom exceeded revenue and EPS expectations, demonstrating U.S. market share gains and solid fundamentals. Analysts from …

DexCom stock reaches 52-week high at $82.85

DexCom (DXCM) stock has hit a 52-week high of $82.85, indicating positive market sentiment despite being 6% below its all-time peak. This surge follows impressive second-quarter financial results, with revenues and adjusted EPS exceeding expectations, prompting several analyst firms to raise their price targets …

DexCom DXCM Jumps After Earnings Beat And FDA AI Win

DexCom (DXCM) stock surged over 10% following a strong Q2 2026 earnings beat, exceeding revenue and adjusted EPS expectations. The company also raised its full-year guidance and was selected by the FDA for its TEMPO digital health pilot, integrating its AI-driven Glucose Health Program …

Stifel raises DexCom stock price target to $95 on strong results

Stifel has increased its price target for DexCom Inc. (NASDAQ:DXCM) to $95 from $90, maintaining a Buy rating, following the company's strong second-quarter results which surpassed expectations in revenue, gross margin, operating margin, and EPS. DexCom also raised its 2026 guidance and appears to …

Stifel eleva el precio objetivo de DexCom a 95 dólares tras sólidos resultados

Truist raises DexCom stock price target to $93 on growth outlook

Truist Securities has increased its price target for DexCom (NASDAQ:DXCM) to $93 from $87, maintaining a Buy rating. This adjustment reflects DexCom's strong revenue and EPS growth prospects, expected market expansion, and the upcoming G8 product cycle. The valuation is supported by the company's …

DexCom, Inc. Stock 12‑Month Price Target Raised to $90.25, Implies 21% Upside

DexCom, Inc.'s average 12-month stock price target has been increased from $86.46 to $90.25, suggesting a 21% potential upside based on the Jul. 30 closing price. This revised target is based on estimates from 24 analysts, with forecasts ranging from $77 to $115 per …

Truist Raises Price Target on DexCom to $93 From $87, Keeps Buy Rating

Truist has increased its price target for DexCom (DXCM) to $93 from $87, while maintaining a "Buy" rating on the stock. This adjustment reflects an updated outlook from the analytical firm. DexCom specializes in continuous glucose monitoring (CGM) systems for individuals with diabetes.

DexCom, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:DXCM) 2026-07-31

DexCom gains as investors appear to welcome earnings momentum and growth outlook

DexCom Stock Up on Q2 Earnings & Revenue Beat, Margins Rise

Earnings call transcript: Dexcom tops Q2 2026 estimates and lifts outlook

Dexcom (DXCM) reported Q2 2026 earnings and revenue that exceeded Wall Street estimates, leading the glucose-monitoring company to raise its full-year outlook. The company's adjusted EPS was $0.70 on revenue of $1.31 billion, surpassing analyst expectations of $0.61 per share and $1.29 billion in …

Informe de resultados de Dexcom: supera estimaciones del Q2 2026 y mejora perspectivas

Dexcom Inc 2026: Revenue $1.31B, EPS $0.64— 10-Q Summary

Dexcom Inc reported strong second-quarter 2026 results, with revenue reaching $1.31 billion and diluted EPS of $0.64, significantly exceeding prior-year figures. The growth was driven by increased disposable sensor volume, expanded customer base, and improved gross margins, supported by new product introductions like the …

DexCom (NASDAQ: DXCM) grows Q2 2026 profit, boosts buybacks and cash

DexCom reported strong financial results for Q2 2026, with revenue up 13% to $1.31 billion and net income increasing 39% to $249.1 million. The company's gross margin expanded to 63.4%, and operating income rose 50%. DexCom also repurchased 8.6 million shares for $600 million …

DexCom’s (NASDAQ:DXCM) Q2 CY2026 Sales Beat Estimates

Dexcom beats Q2 estimates, raises guidance; Shares rise 2%

DexCom (NASDAQ:DXCM) announced strong second-quarter results, surpassing analyst expectations for both earnings per share and revenue, leading to a 2.2% increase in its shares. The company also raised its fiscal 2026 revenue guidance and improved its outlook for adjusted gross profit and operating margins. …

Dexcom raises annual revenue forecast on strong demand for glucose monitors

Dexcom, a medical device maker, raised its full-year revenue forecast and surpassed quarterly estimates, driven by the sustained high demand for its continuous glucose monitors. The company reported a 13% increase in second-quarter revenue to $1.31 billion and an adjusted profit of 70 cents …

Dexcom übertrifft Q2-Schätzungen und hebt Prognose an – Aktie steigt um 2 %

Earnings Flash (DXCM) DexCom, Inc. Reports Q2 Revenue $1.31B, vs. FactSet Est of $1.29B

DexCom, Inc. (DXCM) reported Q2 revenue of $1.31 billion, surpassing FactSet's estimate of $1.29 billion. The company also announced an adjusted EPS of $0.70 per share for Q2, exceeding FactSet's estimate of $0.61. Following these strong results, Dexcom raised its annual revenue forecast to …

Earnings Flash (DXCM) DexCom, Inc. Posts Q2 Adjusted EPS $0.70 per Share, vs. FactSet Est of $0.61

DexCom, Inc. reported adjusted earnings per share of $0.70 for the second quarter, surpassing FactSet's estimate of $0.61. This news comes as the company also recently increased its annual revenue forecast due to strong demand for its glucose monitors. The financial results highlight a …